Ligand Acquires Portfolio of Synthetic Royalty and Milestone Rights from CorMatrix® Cardiovascular for $17.5 Million May 4, 2016
Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences April 22, 2016
Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP April 7, 2016
Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection March 15, 2016
Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock December 17, 2015
RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs December 8, 2015
